Literature DB >> 17954483

Update on clinical gene therapy in childhood.

Waseem Qasim1, H Bobby Gaspar, Adrian J Thrasher.   

Abstract

The successful use of gene therapy to correct rare immune system disorders has highlighted the enormous potential of such therapies. We review the current state of gene therapy for childhood immune system disorders, and consider why these conditions have been particularly amenable to genetic correction. As with all emerging therapies, there have been unexpected side effects and their underlying mechanisms are the subject of intense research. Minimising such risks through improved vector design will play an important role in developing the next generation of gene based therapies and extending their applicability.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17954483      PMCID: PMC2083628          DOI: 10.1136/adc.2006.108787

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  30 in total

1.  Diversity, functionality, and stability of the T cell repertoire derived in vivo from a single human T cell precursor.

Authors:  P Bousso; V Wahn; I Douagi; G Horneff; C Pannetier; F Le Deist; F Zepp; T Niehues; P Kourilsky; A Fischer; G de Saint Basile
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-04       Impact factor: 11.205

Review 2.  Primary immunodeficiency diseases: an experimental model for molecular medicine.

Authors:  A Fischer
Journal:  Lancet       Date:  2001-06-09       Impact factor: 79.321

3.  A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency.

Authors:  Salima Hacein-Bey-Abina; Christof von Kalle; Manfred Schmidt; Françoise Le Deist; Nicolas Wulffraat; Elisabeth McIntyre; Isabelle Radford; Jean-Luc Villeval; Christopher C Fraser; Marina Cavazzana-Calvo; Alain Fischer
Journal:  N Engl J Med       Date:  2003-01-16       Impact factor: 91.245

4.  HIV-1 integration in the human genome favors active genes and local hotspots.

Authors:  Astrid R W Schröder; Paul Shinn; Huaming Chen; Charles Berry; Joseph R Ecker; Frederic Bushman
Journal:  Cell       Date:  2002-08-23       Impact factor: 41.582

5.  Prolonged pancytopenia in a gene therapy patient with ADA-deficient SCID and trisomy 8 mosaicism: a case report.

Authors:  Barbara C Engel; Greg M Podsakoff; Joanna L Ireland; E Monika Smogorzewska; Denise A Carbonaro; Kathy Wilson; Ami Shah; Neena Kapoor; Mirna Sweeney; Mark Borchert; Gay M Crooks; Kenneth I Weinberg; Robertson Parkman; Howard M Rosenblatt; Shi-Qi Wu; Michael S Hershfield; Fabio Candotti; Donald B Kohn
Journal:  Blood       Date:  2006-09-14       Impact factor: 22.113

6.  Persistence and expression of the adenosine deaminase gene for 12 years and immune reaction to gene transfer components: long-term results of the first clinical gene therapy trial.

Authors:  Linda Mesler Muul; Laura M Tuschong; Sherry Lau Soenen; G Jayashree Jagadeesh; W Jay Ramsey; Zhifeng Long; Charles S Carter; Elizabeth K Garabedian; Melinna Alleyne; Margaret Brown; Wendy Bernstein; Shepherd H Schurman; Thomas A Fleisher; Susan F Leitman; Cynthia E Dunbar; R Michael Blaese; Fabio Candotti
Journal:  Blood       Date:  2002-11-27       Impact factor: 22.113

7.  Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy.

Authors:  Salima Hacein-Bey-Abina; Françoise Le Deist; Frédérique Carlier; Cécile Bouneaud; Christophe Hue; Jean-Pierre De Villartay; Adrian J Thrasher; Nicolas Wulffraat; Ricardo Sorensen; Sophie Dupuis-Girod; Alain Fischer; E Graham Davies; Wietse Kuis; Lilly Leiva; Marina Cavazzana-Calvo
Journal:  N Engl J Med       Date:  2002-04-18       Impact factor: 91.245

8.  Long-term survival and transplantation of haemopoietic stem cells for immunodeficiencies: report of the European experience 1968-99.

Authors:  Corinne Antoine; Susanna Müller; Andrew Cant; Marina Cavazzana-Calvo; Paul Veys; Jaak Vossen; Anders Fasth; Carsten Heilmann; Nicolas Wulffraat; Reinhard Seger; Stéphane Blanche; Wilhelm Friedrich; Mario Abinun; Graham Davies; Robert Bredius; Ansgar Schulz; Paul Landais; Alain Fischer
Journal:  Lancet       Date:  2003-02-15       Impact factor: 79.321

9.  Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning.

Authors:  Alessandro Aiuti; Shimon Slavin; Memet Aker; Francesca Ficara; Sara Deola; Alessandra Mortellaro; Shoshana Morecki; Grazia Andolfi; Antonella Tabucchi; Filippo Carlucci; Enrico Marinello; Federica Cattaneo; Sergio Vai; Paolo Servida; Roberto Miniero; Maria Grazia Roncarolo; Claudio Bordignon
Journal:  Science       Date:  2002-06-28       Impact factor: 47.728

10.  Immune reconstitution in ADA-SCID after PBL gene therapy and discontinuation of enzyme replacement.

Authors:  Alessandro Aiuti; Sergio Vai; Alessandra Mortellaro; Giulia Casorati; Francesca Ficara; Grazia Andolfi; Giuliana Ferrari; Antonella Tabucchi; Filippo Carlucci; Hans D Ochs; Luigi D Notarangelo; Maria Grazia Roncarolo; Claudio Bordignon
Journal:  Nat Med       Date:  2002-05       Impact factor: 53.440

View more
  4 in total

1.  Gene therapy's out-of-body experience.

Authors:  Christopher Thomas Scott; Laura DeFrancesco
Journal:  Nat Biotechnol       Date:  2016-06-09       Impact factor: 54.908

Review 2.  Recent advances in gene therapy for severe congenital immunodeficiency diseases.

Authors:  Robert Sokolic; Chimene Kesserwan; Fabio Candotti
Journal:  Curr Opin Hematol       Date:  2008-07       Impact factor: 3.284

Review 3.  Partially corrected X-linked severe combined immunodeficiency: long-term problems and treatment options.

Authors:  Suk See De Ravin; Harry L Malech
Journal:  Immunol Res       Date:  2009       Impact factor: 4.505

Review 4.  Gene and cell therapy for children--new medicines, new challenges?

Authors:  Karen F Buckland; H Bobby Gaspar
Journal:  Adv Drug Deliv Rev       Date:  2014-02-28       Impact factor: 15.470

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.